174 related articles for article (PubMed ID: 20945149)
1. Oral bisphosphonates and risk of ischemic stroke: a case-control study.
Christensen S; Mehnert F; Chapurlat RD; Baron JA; Sørensen HT
Osteoporos Int; 2011 Jun; 22(6):1773-9. PubMed ID: 20945149
[TBL] [Abstract][Full Text] [Related]
2. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
[TBL] [Abstract][Full Text] [Related]
3. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA
BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527
[TBL] [Abstract][Full Text] [Related]
4. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
[TBL] [Abstract][Full Text] [Related]
5. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
Loke YK; Jeevanantham V; Singh S
Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer.
Wilkinson GS; Baillargeon J; Kuo YF; Freeman JL; Goodwin JS
J Clin Oncol; 2010 Nov; 28(33):4898-905. PubMed ID: 20940190
[TBL] [Abstract][Full Text] [Related]
8. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.
Rodríguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study.
Spoendlin J; Meier C; Jick SS; Meier CR
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis.
Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S
Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644
[TBL] [Abstract][Full Text] [Related]
12. Saving bones without risking brain-bisphosphonates and risk of stroke: matched case-control study.
Asghar ZB; Godoy Caballero A; Pathirannehelage S; Williams J; McKay S; Grassby P; de Lusignan S; Niroshan Siriwardena A
Osteoporos Int; 2019 Sep; 30(9):1845-1854. PubMed ID: 31214750
[TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
Rhee CW; Lee J; Oh S; Choi NK; Park BJ
Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Abrahamsen B; Eiken P; Brixen K
J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.
Christiansen CF; Christensen S; Mehnert F; Cummings SR; Chapurlat RD; Sørensen HT
Arch Intern Med; 2009 Oct; 169(18):1677-83. PubMed ID: 19822824
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
Pazianas M; Blumentals WA; Miller PD
Osteoporos Int; 2008 Jun; 19(6):773-9. PubMed ID: 17999023
[TBL] [Abstract][Full Text] [Related]
18. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study.
Erichsen R; Christiansen CF; Frøslev T; Jacobsen J; Sørensen HT
Br J Cancer; 2011 Sep; 105(7):881-3. PubMed ID: 21878939
[TBL] [Abstract][Full Text] [Related]
19. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.
Etminan M; Aminzadeh K; Matthew IR; Brophy JM
J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310
[TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Grosso A; Douglas I; Hingorani A; MacAllister R; Smeeth L
PLoS One; 2009; 4(3):e4720. PubMed ID: 19266096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
